Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.
In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.
Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."
Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.
A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.
In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.
The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."
Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."
PLOS Biology has asked researchers how they envision the future of genetics and genomics.
NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.
In Science this week: caution urged in use of gene drives, and more.
The US is heading toward another budget showdown, Nature News says.
A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.
The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.
In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.
The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.
Ivan Oransky discusses the need for reproducibility research at The Conversation.
Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."
In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.
Jun Wang, the chief executive of BGI, has stepped down.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.
The NIH has issued a preliminary guidance for newborn dried blood spot research.